DOCSLIB.ORG

Register by June 12 and Save up to $600

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Register by June 12 and Save up to $600 REGISTER BY JUNE 12 AND SAVE UP TO $600 Organized by Cambridge Healthtech The Industry’s Preeminent Event on Novel Drug Targets Institute 13th Annual September 21-24, 2015 Westin Boston Waterfront | Boston, MA SEPTEMBER 22 - 23 SEPTEMBER 23 - 24 n Targeting Epigenetic Readers and Chromatin Remodelers n Targeting Histone Methyltransferases and Demethylases n Targeting the Ubiquitin Proteasome System n Targeting the Unfolded Protein Response n Targeting the Microbiome n Kinase Inhibitor Discovery n GPCR-Based Drug Discovery - Part 1 n GPCR-Based Drug Discovery - Part 2 n Antibodies Against Membrane Protein Targets - Part 1 n Antibodies Against Membrane Protein Targets - Part 2 n RNAi for Functional Genomics Screening n New Frontiers in Gene Editing n Gene Therapy Breakthroughs n Quantitative Systems Pharmacology n Targeting Ocular Disorders SYMPOSIA Plenary Session Speakers SEPTEMBER 21 PLENARY KEYNOTE INTRODUCTION: Comprehensive Sponsored by n Next-Generation Histone Deacetylase Inhibitors Kinase and Epigenetic Compound Profiling n Strategies for Rare Diseases Kelvin Lam, Ph.D. SEPTEMBER 22 Director, Strategic Partnerships, Reaction Biology Corporation n Developing CRISPR-Based Therapies iPS Cell Technology, Gene Editing and Disease Research EVENT FEATURES Rudolf Jaenisch, M.D. Founding Member, Whitehead Institute for Biomedical Research; n 15 Conferences n 15 Short Courses Professor, Department of Biology, Massachusetts Institute of Technology n 3 Symposia n 65 Exhibitors n 130+ Posters n Plenary Keynote Speakers The Evolutionary Dynamics and Treatment of Cancer Martin Nowak, Ph.D., M.Sc. n 40+ Interactive Breakout Discussion Groups Professor, Biology and Mathematics and Director, Program for Evolutionary Dynamics, Harvard University DiscoveryOnTarget.com PREMIER SPONSORS CONFERENCE-AT-A-GLANCE *Separate registration required for Short Courses and Symposia Monday Tuesday - Wednesday a.m. Wednesday p.m. - Thursday Pre-Conference T1A: Targeting Epigenetic Readers and Chromatin Remodelers T1B: Targeting Histone Methyltransferases and Demethylases Short Courses T2A: Targeting the Ubiquitin Protesome System T2B: Targeting the Unfolded Protein Response S1: Symposium: T3A: Targeting the Microbiome T3B: Kinase Inhibitor Discovery Next Generation Histone Deacetylase GPCR-Based Drug Discovery – Part 1 GPCR-Based Drug Discovery – Part 2 Inhibitors T4A: T4B: T5A: Antibodies Against Membrane Protein Targets – Part 1 T5B: Antibodies Against Membrane Protein Targets – Part 2 T6A: RNAi for Functional Genomics Screening T6B: New Frontiers in Gene Editing S2: Symposium: Strategies for Rare T7A: Gene Therapy Breakthroughs T7B: Quantitative Systems Pharmacology Diseases T8A: Targeting Ocular Disorders Wednesday 7-9:30 pm - Dinner Short Courses S3: Symposium: Tuesday Designing CRISPR-Based Therapies PLENARY KEYNOTE PROGRAM ambridge Healthtech Institute will host its 13th Annual Discovery on Target event PLENARY KEYNOTE INTRODUCTION: showcasing current and emerging “hot” Comprehensive Kinase and Epigenetic Compound Profiling Sponsored by C targets for the pharmaceutical industry September Kelvin Lam, Ph.D., Director, Strategic Partnerships, Reaction Biology Corporation 21-24, 2015 in Boston, MA. Spanning five days, the Kinase inhibitors can be used as chemical probes to understand signal transduction event attracts 1,000+ attendees (from 21 countries), pathways. Since the majority of kinase probes inhibit multiple kinases, composed of scientists/technologists, executives, understanding the off-target effects will allow scientists to design better poly-pharmacologic directors, and managers from biopharma, academic, compounds to meet specific therapeutic needs. Profiling a compound against the entire and healthcare organizations. In 2015 the event is kinase gene family will allow us to understand the compound’s full enzymatic activities. comprised of 15 conference tracks, 3 Symposia, Unexpected activities could lead to different chemical design and possibly novel therapeutic 15 short courses, 35+ interactive breakout opportunities. Reaction Biology offers large-scale in vitro kinase and epigenetic profiling discussion groups, an exhibit hall of 65 companies, services for (1) compound prioritizing and (2) elucidating novel activities for kinase and epigenetic inhibitors. and dedicated poster viewing and networking sessions. The 13th Annual Discovery on Target iPS Cell Technology, Gene Editing and Disease Research event assembles an impressive group of 200+ Rudolf Jaenisch, M.D., Founding Member, Whitehead Institute for Biomedical distinguished speakers who look forward to sharing Research; Professor, Department of Biology, Massachusetts Institute of their knowledge, best practices, and expertise with Technology all attendees. The development of the iPS cell technology has revolutionized our ability to study human diseases in definedin vitro cell culture systems. A major problem of using iPS cells for this “disease in the dish” approach is the choice of control cells because the unpredictable Maximize your experience on-site at Discovery on variability between different iPS / ES cells to differentiate into a given lineage. Recently Target 2015! developed efficient gene editing methods such as the CRISPR/Cas system allow the creation The Intro-Net offers you the of genetically defined models of monogenic as well as polygenic human disorders. opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to The Evolutionary Dynamics and Treatment of Cancer connect to the key people you want to meet. This online Martin Nowak, Ph.D., M.Sc., Professor, Biology and Mathematics and Director, system was designed with your privacy in mind and is Program for Evolutionary Dynamics, Harvard University available only to registered session attendees of this Cancer is an evolutionary process. Cancer initiation and progression are caused by event. Registered conference attendees will receive more somatic mutation and selection of dividing cells. The mathematical theory of evolution can information on accessing the Intro-Net in the weeks leading therefore provide quantitative insights into human cancer. up to the event. PREMIER SPONSORS CORPORATE SPONSORS Eurofins Pharma Discovery Services 2 | Discovery on Target PRESENT A POSTER AND SAVE $50! Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by August 7, 2015. • Your poster will be available to 1,000+ delegates • You’ll automatically be entered into our poster competition where two winners each will receive an American Express Gift Certificate • $50 off your registration fee • Your research will be seen by leaders from pharmaceutical, biotech, academic and government institutes Discovery on Target Student Fellowship Full time graduate students and PhD Candidates are encouraged to apply for the Discovery on Target Student Fellowship. Interested students must complete an online application for the 2015 Student Fellowship. Applications are due by July 10, 2015. How Students Benefit from Presenting a Poster: 1. Showcase Your Research to 1,000+ 2. Start a Future Collaboration and Meet a 3. Expand Your Network: When you return to Attendees: Within the expansive Exhibit Potential Employer: Collect business cards school/lab, add each person you meet to Hall stand by your poster and network and meet prospective collaborators who may your LinkedIn connections. Keep in touch with attendees. Distribute copies of journal be actively pursuing work in your field. Put to share new ideas that may advance articles or papers you have authored or together a short outline of the field(s) in which your own research or stature in the contributed to. you seek collaborators or new professional scientific community. challenges, and distribute those to the people you meet. 2014 ATTENDEE DEMOGRAPHICS COMPANY TYPE COMPANY TITLE GEOGRAPHIC LOCATION Services/Societies: 2% Sales/Marketing/ Manager: 6% Asia: 8% Government: 3% Assistant: 7% Financial: 1% Scientist/ Europe: 18% Other: 1% Technologist: 45% Healthcare/ Professor : 15% Hospital: 5% USA Breakdown: East Coast: 69% West Coast: 19% Midwest: 12% Academic: 25% Biotech/ Commercial: USA: 73% Pharma: 31% 33% Executive/Director: 27% HOTEL & TRAVEL INFORMATION CONFERENCE VENUE AND HOST HOTEL: Top Reasons to Stay at the Westin Boston Waterfront Hotel Westin Boston Waterfront • Take advantage of the deeply discounted $279 group rate! 425 Summer St. | Boston, MA 02210 | T: 617-532-4600 • No Commute, since meeting takes place at hotel. Discounted Room Rate: $279 s/d • Lots of new restaurants within walking distances. Waterfront is Discount Reservation Cut-off Date: August 25, 2015 Boston’s hot new neighborhood! Reservations: Please visit the travel page of • Complimentary wireless internet access in guest rooms. www.DiscoveryOnTarget.com Discovery on Target | 3 SHORT COURSES MONDAY, SEPTEMBER 21, 8:00-11:00 AM SC5: GPCR Structure-Based Drug Discovery Recent breakthroughs in obtaining high resolution structures of G Protein- SC1: Cancer Metabolism: Coupled Receptors (GPCRs) are rapidly impacting the pharmaceutical industry. This course will review how newly elucidated GPCR crystal structures have Pathways, Targets and Clinical Updates informed our current understanding of GPCR function. The instructors will Cancer cells, to fuel their
Load more

Recommended publications
  • Opportunities and Challenges in Phenotypic Drug Discovery: an Industry Perspective
    PERSPECTIVES Nevertheless, there are still challenges in OPINION prospectively understanding the key success factors for modern PDD and how maximal Opportunities and challenges in value can be obtained. Articles published after the analysis by Swinney and Anthony have re-examined the contribution of PDD phenotypic drug discovery: an to new drug discovery6,7 and have refined the conditions for its successful application8. industry perspective Importantly, it is apparent on closer examination that the classification of drugs John G. Moffat, Fabien Vincent, Jonathan A. Lee, Jörg Eder and as ‘phenotypically discovered’ is somewhat Marco Prunotto inconsistent6,7 and that, in fact, the majority of successful drug discovery programmes Abstract | Phenotypic drug discovery (PDD) approaches do not rely on knowledge combine target knowledge and functional of the identity of a specific drug target or a hypothesis about its role in disease, in cellular assays to identify drug candidates contrast to the target-based strategies that have been widely used in the with the most advantageous molecular pharmaceutical industry in the past three decades. However, in recent years, there mechanism of action (MoA). Although there is clear evidence that phenotypic has been a resurgence in interest in PDD approaches based on their potential to screening can be an attractive proposition address the incompletely understood complexity of diseases and their promise for efficiently identifying functionally of delivering first-in-class drugs, as well as major advances in the tools for active hits that lead to first-in-class drugs, cell-based phenotypic screening. Nevertheless, PDD approaches also have the gap between a screening hit and an considerable challenges, such as hit validation and target deconvolution.
    [Show full text]
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • Current Screening Methodologies in Drug Discovery for Selected Human Diseases
    marine drugs Review Current Screening Methodologies in Drug Discovery for Selected Human Diseases Olga Maria Lage 1,2,*, María C. Ramos 3, Rita Calisto 1,2, Eduarda Almeida 1,2, Vitor Vasconcelos 1,2 ID and Francisca Vicente 3 1 Departamento de Biologia, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre s/nº 4169-007 Porto, Portugal; [email protected] (R.C.); [email protected] (E.A.); [email protected] (V.V.) 2 CIIMAR/CIMAR–Centro Interdisciplinar de Investigação Marinha e Ambiental–Universidade do Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos, Portugal 3 Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Parque Tecnológico de Ciencias de la Salud, 18016 Granada, Spain; [email protected] (M.C.R.); [email protected] (F.V.) * Correspondence: [email protected]; Tel.: +351-22-0402724; Fax.: +351-22-0402799 Received: 7 August 2018; Accepted: 11 August 2018; Published: 14 August 2018 Abstract: The increase of many deadly diseases like infections by multidrug-resistant bacteria implies re-inventing the wheel on drug discovery. A better comprehension of the metabolisms and regulation of diseases, the increase in knowledge based on the study of disease-born microorganisms’ genomes, the development of more representative disease models and improvement of techniques, technologies, and computation applied to biology are advances that will foster drug discovery in upcoming years. In this paper, several aspects of current methodologies for drug discovery of antibacterial and antifungals, anti-tropical diseases, antibiofilm and antiquorum sensing, anticancer and neuroprotectors are considered.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • 2019 Analyst Day
    2019 Analyst Day March 12, 2019 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it’s partners’ judgment as of the date of this presentation. Words such as “plans,” “believes,” “expects,” “projects,” “could,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs, potential uses of capital, including any potential dividend or share repurchase program, and the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherit in Ligand’s business, including: Ligand has wide discretion on its use of capital and may choose not to engage in any share repurchases, declare any dividends or pursue acquisitions or internal develop programs; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline;, drug development program benefits may not be realized; Ligand will achieve its guidance in 2019 or thereafter; third party research summarized herein may not be correct or complete; Kyprolis®, EVOMELA® and Zulresso™ may not perform as expected, Ligand relies on collaborative partners for milestone and royalty payments,
    [Show full text]
  • Form 8-K Ligand Pharmaceuticals
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2020 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.) 3911 Sorrento Valley Boulevard, Suite 110 San Diego CA 92121 (Address of principal executive offices) (Zip Code) (858) 550-7500 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    [Show full text]
  • An Emerging Strategy for Rapid Target and Drug Discovery
    R E V I E W S CHEMOGENOMICS: AN EMERGING STRATEGY FOR RAPID TARGET AND DRUG DISCOVERY Markus Bredel*‡ and Edgar Jacoby§ Chemogenomics is an emerging discipline that combines the latest tools of genomics and chemistry and applies them to target and drug discovery. Its strength lies in eliminating the bottleneck that currently occurs in target identification by measuring the broad, conditional effects of chemical libraries on whole biological systems or by screening large chemical libraries quickly and efficiently against selected targets. The hope is that chemogenomics will concurrently identify and validate therapeutic targets and detect drug candidates to rapidly and effectively generate new treatments for many human diseases. Over the past five decades, pharmacological compounds however, that owing to the emergence of various sub- TRANSCRIPTIONAL PROFILING The study of the transcriptome have been identified that collectively target the products specialties of chemogenomics (discussed in the next — the complete set of RNA of ~400–500 genes in the human body; however, only section) and the involvement of several disciplines, it is transcripts that are produced by ~120 of these genes have reached the market as the tar- currently almost impossible to give a simple and com- the genome at any one time — gets of drugs1,2. The Human Genome Project3,4 has mon definition for this research discipline (BOX 1). using high-throughput methods, such as microarray made available many potential new targets for drug In chemogenomics-based drug discovery, large col- analysis. intervention: several thousand of the approximately lections of chemical products are screened for the paral- 30,000–40,000 estimated human genes4 could be associ- lel identification of biological targets and biologically ated with disease and, similarly, several thousand active compounds.
    [Show full text]
  • Council for Scientific and Industrial Research
    ANNUAL 2018/19 PO Box 395, Pretoria, 0001, South Africa Published by: CSIR Communication Enquiries: Tel +27 12 841 2911 • Email: [email protected] ISBN-13 978-0-7988-5643-0 “The objects of the CSIR are, through directed and particularly multi-disciplinary research and technological innovation, to foster, in the national interest and in fields which in its opinion should receive preference, industrial and scientific development, either by itself or in co-operation with principals from the private or public sectors, and thereby to contribute to the improvement of the quality of life of the people of the Republic, and to perform any other functions that may be assigned to the CSIR by or under this Act.” (Scientific Research Council Act 46 of 1988, as amended by Act 27 of 2014) CONTENTS The CSIR at a glance ......................................................2 From our leadership .......................................................6 Organisational highlights .............................................. 24 Financial sustainability and governance .......................... 66 Executive report ........................................................... 87 Consolidated financial statements ................................ 101 Knowledge dissemination ............................................ 148 Abbreviations ............................................................ 175 1 INTRODUCTION THE CSIR AT A GLANCE 2 342 TOTAL STAFF BASE 1 608 1 610 1 041 *SET BASE BLACK SOUTH FEMALE SOUTH AFRICANS AFRICANS *Science, engineering and technology
    [Show full text]
  • Milner Symposium 2020
    THERAPEUTICS SYMPOSIUM 2020 GLOBAL THERAPEUTIC ALLIANCE OVERVIEW A SERIES OF ONLINE EVENTS STARTING ON JUNE 12TH ALLIANCE GLOBAL THERAPEUTIC ALLIANCE The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration. GLOBAL THERAPEUTIC ALLIANCE Research in the Milner Therapeutics Institute is funded by: Our outreach programme is through the Global Therapeutic Alliance, which aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The Milner Therapeutics Consortium is central to this aim (p4), and the Alliance has been expanded with the Affiliated Company p8( ) and Affiliated Institutions scheme p37( ) to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge. The Affiliated Venture Partnersprogramme, operational since October 2017, provides mentoring and potential funding opportunities for the Milner Therapeutics Institute and its Global Therapeutic Alliance, and especially for our in-house company accelerator Start Codon. 3 CONSORTIUM ASTEX PHARMACEUTICALS MILNER THERAPEUTICS CONSORTIUM The Milner Therapeutics Astex is a leader in innovative drug discovery and Consortium is an academic- development, committed to the fight against cancer and industry partnership, active since diseases of the central nervous system. Astex is developing June 2015. This is underpinned a proprietary pipeline of novel therapies and has multiple
    [Show full text]
  • High Content Phenotypic Profiling in Oesophageal Adenocarcinoma Identifies Selectively
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.20.912212; this version posted January 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. High Content Phenotypic Profiling in Oesophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery Rebecca E Hughes1, Richard J R Elliott1, Alison F Munro1, Ashraff Makda1, J Robert O’Neill2, Ted Hupp1, Neil O Carragher1 Affiliations 1MRC Institute of Genetics & Molecular Medicine, The University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XR 2Cambridge Oesophagogastric Unit, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 2QQ. Corresponding Author: Professor Neil Carragher Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR United Kingdom Email: [email protected] Keywords: Oesophageal Adenocarcinoma, Phenotypic, High-content, Mechanism-of- Action, Machine Learning bioRxiv preprint doi: https://doi.org/10.1101/2020.01.20.912212; this version posted January 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Oesophageal adenocarcinoma (OAC) is a highly heterogeneous disease, dominated by large-scale genomic rearrangements and copy number alterations. Such characteristics have hampered conventional target-directed drug discovery and personalized medicine strategies contributing to poor outcomes for patients diagnosed with OAC.
    [Show full text]
  • 4586728.98 in 2005
    Detail Awards by Sponsor Dept Name FY05 Award Federal National Cancer Institute 47,048,096.55 National Institute of Heart, Lung, and Blood 38,794,591.33 National Institute of General Medicine Science 30,400,147.18 National Institute of Child Health & Human Development 29,863,697.92 National Institute of Allergy & Infectious Diseases 27,492,973.12 National Science Foundation - Research 20,659,748.00 National Institute of Diabetes, Digestive & Kidney Diseases 19,575,845.00 National Center for Research Resources 19,179,710.00 National Institute of Mental Health-NIH 16,727,938.80 US Department of Education 15,868,100.00 US Agency for International Development 12,743,904.00 National Institute of Environmental Health Sciences 11,961,787.00 National Institute of Neurologic Disorders and Stroke 11,957,697.00 Centers for Disease Control 10,507,132.00 National Institute of Dental and Craniofacial Research 7,032,009.35 National Institute on Alcohol Abuse & Alcoholism 6,874,910.00 Bureau of Health Professions 5,797,479.00 National Institute of Arthritis Musculoskeletal Skin Disease 4,921,205.00 US Environmental Protection Agency - GRANTS 4,586,728.98 National Institute on Aging 4,159,889.94 National Institute on Drug Abuse 4,111,248.00 National Institute of Nursing Research 4,094,244.00 National Institute of Biomedical Imaging and Bioengineering 4,079,842.59 Maternal and Child Health Bureau 4,049,730.00 National Science Foundation - Training 3,877,378.00 National Center for Chronic Disease Prev & Health Promo(CDC) 3,384,180.00 US Department of Defense
    [Show full text]
  • An Insight Into Our Life Sciences and Healthcare Sector
    An insight into our Life Sciences and Healthcare Sector 2020 allenovery.com 2 An insight into our Life Sciences and Healthcare Sector | 2020 © Allen & Overy LLP 2020 3 Contents Introducing Allen & Overy 04 Full service, international support for the life sciences and healthcare sector 05 M&A/corporate finance 06 Licensing and collaborations 09 Patent litigation 11 Regulatory 13 Dispute resolution/arbitration 14 Equity and debt financing 15 Restructuring 16 Key contacts 17 allenovery.com 4 An insight into our Life Sciences and Healthcare Sector | 2020 Introducing Allen & Overy GEOGRAPHIC SPLIT BY TOTAL NUMBER OF LAWYERS† 141 Central & Eastern Europe 1,016 UK 929 Western Europe 440 129 Asia Pacific 185 Middle East North, Central & South America 77 Africa GLOBAL PRESENCE NORTH AMERICA EUROPE AFRICA ASIA PACIFIC New York Amsterdam Istanbul Casablanca Bangkok Seoul Washington, D.C. Antwerp London Johannesburg Beijing Shanghai Barcelona Luxembourg Hanoi Singapore CENTRAL & Belfast Madrid MIDDLE EAST Ho Chi Minh City Sydney SOUTH AMERICA Bratislava Milan Abu Dhabi Hong Kong Tokyo São Paulo Brussels Moscow Dubai Jakarta* Yangon Bucharest* Munich Perth * Associated office Budapest Paris ** Cooperation office Düsseldorf Prague † All figures represent the Frankfurt Rome financial year 2016/17 Hamburg Warsaw Source: Regional active headcount October 2018 KEY STATISTICS 5,400 2,300 550 40+ Number of staff Number of lawyers Number of partners Offices around the world © Allen & Overy LLP 2020 5 Full service, international support for the life sciences and healthcare sector Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.
    [Show full text]